Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

BACKGROUND: Pembrolizumab demonstrated robust antitumor activity and safety in the phase Ib KEYNOTE-001 study (NCT01295827) of advanced melanoma. Five-year outcomes in all patients and treatment-naive patients are reported herein. Patients whose disease progressed following initial response and who...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamid, O, Robert, C, Daud, A, Hodi, F S, Hwu, W J, Kefford, R, Wolchok, J D, Hersey, P, Joseph, R, Weber, J S, Dronca, R, Mitchell, T C, Patnaik, A, Zarour, H M, Joshua, A M, Zhao, Q, Jensen, E, Ahsan, S, Ibrahim, N, Ribas, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503622/
https://www.ncbi.nlm.nih.gov/pubmed/30715153
http://dx.doi.org/10.1093/annonc/mdz011

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503622/
https://www.ncbi.nlm.nih.gov/pubmed/30715153
http://dx.doi.org/10.1093/annonc/mdz011

Ejemplares similares